EXOZHealthcare · Biotechnology

EXOZ Stock Forecast: eXoZymes, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$7.38

+4.76% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap

$66.4M

Ticker Nerd rank

11 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

+26.7%

+38.5%

YTD

−32.3%

−20.8%

From 52W high

−55.3%

From 52W low

+67.6%

$17

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

EXOZ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores eXoZymes, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

Size

Issuance

Revisions

Volatility

Value

Momentum

Growth

Quality

Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EXOZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EXOZ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EXOZ appears on the weeks it earns a place.

Estimates

EXOZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

eXoZymes, Inc. (EXOZ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −6.8×
Price / sales: —
Price / book: 18.1×
EV / EBITDA: −6.0×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −187.2%
Return on assets: −74.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

EXOZ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
EXOZeXoZymes, Inc.	$66.4M	11
HYFTMindWalk Holdings Corp.	$65.8M	57
BOLDBoundless Bio, Inc.	$67.2M	74
TENXTenax Therapeutics, Inc.	$65.5M	31
IMAImageneBio, Inc.	$65.1M	28
CRDFCardiff Oncology, Inc.	$67.8M	42
MNOVMediciNova, Inc.	$68.3M	94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own eXoZymes, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EXOZ news & analysis

eXoZymes Q2 Earnings Call Highlights

MarketBeat · 20 Aug 2026positive

On its Q2 earnings call, eXoZymes outlined progress toward commercializing its NCT program, reporting a tenfold increase in process productivity versus its March pilot campaign. Management said it expects to select a manufacturing partner by the end of the third quarter and identify a market launch partner toward the end of the fourth quarter.

Why it matters — For eXoZymes watchers, the reported productivity gains and the announced timelines for choosing manufacturing and launch partners signal tangible advancement toward commercializing its NCT program.

eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today

Accesswire · 20 Aug 2026neutral

eXoZymes will report its second quarter 2026 results and host an investor webinar at 5:00 PM Eastern Time on August 20, 2026, to discuss the period ended June 30, 2026 and provide updates on recent business developments.

Why it matters — If eXoZymes watchers missed the release, the webinar will be their source for the company's quarterly financial results and latest business progress.

eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets

Accesswire · 18 Aug 2026positive

eXoZymes reported that its NCT process achieved a 10-fold productivity increase, improving the estimated economics of future commercial-scale manufacturing. According to internal assessments, the estimated manufacturing cost equivalent has fallen more than 100x from the first version of the NCT process to the current optimized version.

Why it matters — The improved NCT process economics could strengthen eXoZymes' competitive position for future commercial-scale manufacturing.

eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026

Accesswire · 11 Aug 2026neutral

eXoZymes, Inc. announced it will host a webinar on Thursday, August 20, 2026 at 5:00 PM Eastern Time to discuss its second quarter 2026 results. A press release detailing the results is expected to be issued prior to the call.

Why it matters — Investors following eXoZymes will want to tune in for the second quarter results, which will provide an update on the company's performance in its AI-enhanced enzyme business.

FAQ

Frequently asked questions about EXOZ stock

How does Ticker Nerd's model rank EXOZ?

As at 22 Aug 2026, eXoZymes, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).

What is the EXOZ stock forecast for 2030?

No analyst covering eXoZymes, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EXOZ are extrapolating price history, which says nothing about the business.

How has EXOZ stock performed over the past year?

eXoZymes, Inc. returned -20.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does eXoZymes, Inc. do?

Exozymes Inc. operates in the biotechnology sector with a focus on developing enzyme-based products for industrial applications.

What is the latest news on EXOZ?

The most recent item we track (MarketBeat, 20 Aug 2026): "eXoZymes Q2 Earnings Call Highlights". On its Q2 earnings call, eXoZymes outlined progress toward commercializing its NCT program, reporting a tenfold increase in process productivity versus its March pilot campaign. Management said it expects to select a manufacturing partner by the end of the third quarter and identify a market launch partner toward the end of the fourth quarter.

Company

About eXoZymes, Inc.

Exozymes Inc. operates in the biotechnology sector with a focus on developing enzyme-based products for industrial applications. The primary function of Exozymes Inc. is to leverage advanced enzymatic solutions to enhance processes across various industries, including pharmaceuticals, agriculture, and biofuels. Through its innovative approach, the company aims to improve efficiency, reduce environmental impact, and provide sustainable alternatives to traditional chemical processes. Exozymes Inc. plays a key role in the market by offering customizable enzyme solutions that cater to specific industrial needs, thereby driving technological advancements and promoting cleaner manufacturing practices. Its presence underscores the importance of biotechnology in revolutionizing conventional methods and addressing global environmental challenges.

CEO Mr. Michael Heltzen · 32 employees · United States · https://www.exozymes.com